MedTrace Logo

Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

NCT02636283 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-12-17

Study results available
· View outcomes & findings →

Summary

This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Entresto

Oral pills

DRUG

Placebo group

The placebo pills

Sponsors & Collaborators

Principal Investigators

  • Otto A Sanchez, M.D., Ph.D. · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2018-11-01
Completion
2018-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02636283 on ClinicalTrials.gov